drugset / Trial / NCT05151848

Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis

NCT05151848

Phase 4 Unknown 100 enrolled Chinese SLE Treatment And Research Group
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a prospective,open-labelled,multi-center,randomized clinical trial.It compares the clinical efficacy and safety of there 2 drugs in the treatment of relapse active Takayasu's arteritis patients.

Timeline

Start
2022-01-05
Primary completion
2026-01-15
Completion
2026-01-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Adalimumab Monoclonal antibody 40 mg Subcutaneous
Comparator Tofacitinib Small molecule 5 mg Oral

Indications